← Company directoryNASDAQ · SEC EDGAR
Neurocrine Biosciences, Inc.
NBIXA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
Neurocrine Biosciences third-quarter 2026 results
Neurocrine Biosciences will release its third-quarter results at 4:00 PM EST on November 2, equivalent to 00:00 in Istanbul on November 3. INGREZZA sales and clinical programs will be in focus.
Neurocrine Biosciences ↗Neurocrine Biosciences third-quarter earnings call
Neurocrine Biosciences management's third-quarter earnings call begins at 4:30 PM EST on November 2, equivalent to 00:30 in Istanbul on November 3.
Neurocrine Biosciences ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
NAVNNavan, Inc.NASDAQ · SEC→NBNioCorp Developments Ltd.NASDAQ · SEC→NBBKNB Bancorp, Inc.NASDAQ · SEC→NBISNebius Group N.V. - Class A Ordinary SharesNASDAQ · SEC→NBPNovaBridge BiosciencesNASDAQ · SEC→NBRGNewbridge Acquisition Limited - Class A Ordinary ShareNASDAQ · SEC→NBRGRNewbridge Acquisition Limited - RightsNASDAQ · SEC→NBRGUNewbridge Acquisition Limited - UnitNASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.